RESUMO
In recent years, a large number of studies have contributed to our understanding of the immunosuppressive mechanisms used by mesenchymal stromal cells (MSC). These include the expression of indoleamine 2,3-dioxygenase (IDO) and the production of soluble immunosuppressive factors, such as, interleukin-10 (IL-10), transforming growth factor ß (TGF-ß) and prostaglandin E2 (PGE2). However, whether these factors represent the only triggers involved in immunosuppression is not clear. Indeed, adding IDO inhibitor or neutralizing antibodies against IL-10 and TGF-ß to mixed lymphocyte reactions failed to prevent T-cell suppression by MSC, suggesting that there is either redundancy in the mechanisms of immunosuppression or the involvement of other factors yet to be described. Galectins, a family of ß-galactoside binding proteins, now emerge as a main regulator of MSC immunosuppressive function. Galectin-1 and galectin-3 are constitutively expressed and secreted by human bone marrow MSC. Inhibition of galectin-1 and galectin-3 gene expression with small interfering RNAs abrogated the suppressive effect of MSC on allogeneic T cells. An increase in our understanding of MSC suppressor mechanisms will offer an insight into the use of these cells in human therapy such as the treatment of graft-versus-host disease, a severe complication after haematopoietic stem cell transplantation.
Assuntos
Galectinas/imunologia , Células-Tronco Mesenquimais/imunologia , Células Estromais/imunologia , Linfócitos T/imunologia , Animais , Regulação da Expressão Gênica , HumanosRESUMO
Human bone marrow-derived mesenchymal stem cells (MSC) are multipotent non-hematopoietic progenitors that have regulatory activity on immune cells. NOD- and Toll-like receptors (NLR, TLR) have several roles in immunity, including those relevant to pathogen recognition and shaping the course of immune responses by controlling gene expression. We have shown that these innate immune receptors are expressed by hematopoietic CD34+ progenitors and MSC. To uncover genes critical in MSC function, first we have used microarray to screen for potential transcripts whose levels are altered in response to NOD-1 and TLR-2 activation, and second we validated some candidate genes using real-time RT-PCR, Western blots and cellular assays. Amongst the altered genes, galectin-3 was upregulated at both mRNA and protein levels in response to TLR-2 activation. Interestingly, MSC secreted galectin-3, a protein known to modulate T-cell proliferation, gene expression, cell adhesion and migration. Knockdown of galectin-3 in MSC using small interfering RNA (siRNA) reduced the immunosuppressive effect of MSC on mixed lymphocyte cultures when compared to cells treated with an irrelevant siRNA (P < 0.05). Collectively, the data emphasize a new role of galectin-3 in the immunomodulatory function of MSC and indicate that NOD signalling pathway is also functional in these cells.
Assuntos
Galectina 3/imunologia , Imunomodulação/imunologia , Células-Tronco Mesenquimais/imunologia , Transdução de Sinais/imunologia , Linfócitos T/imunologia , Western Blotting , Proliferação de Células , Galectina 3/metabolismo , Expressão Gênica , Perfilação da Expressão Gênica , Regulação da Expressão Gênica/imunologia , Humanos , Teste de Cultura Mista de Linfócitos , Células-Tronco Mesenquimais/metabolismo , Proteína Adaptadora de Sinalização NOD1/imunologia , Proteína Adaptadora de Sinalização NOD1/metabolismo , Análise de Sequência com Séries de Oligonucleotídeos , RNA Interferente Pequeno , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Linfócitos T/metabolismo , Transfecção , Transplante HomólogoRESUMO
The therapeutic use of the immune system to attack cancer cells has been a longstanding vision among tumour immunologists. However, most human tumours are poorly immunogenic and are able to invade the host immune system. Although these obstacles are clearly critical to cancer vaccine development, the induction of a strong anti-tumour immune response may rely on the activation of high affinity T cells through a molecular mimicry mechanism which involves cross-reactive recognition of foreign antigens mimicking the structure of tumour proteins. Taking into account the disparity in HLA molecules needed to present shared antigens; in late 1990s Stauss et al. described the possibility of generating allorestricted high affinity cytotoxic T cells against synthetic self-peptides bound to non-self-MHC molecules. In addition to the strategies indicated above, the inhibition of the immunosuppressive mechanisms associated with tumour invasion of the immune system using RNA interference also offers a new approach to vaccine design. This review highlights the problem of immune tolerance, the induction of autoreactive T cells, and describes strategies to enhance tumour immunity.
Assuntos
Autoimunidade/imunologia , Vacinas Anticâncer/imunologia , Células Dendríticas/imunologia , Tolerância Imunológica/imunologia , Neoplasias/terapia , Subpopulações de Linfócitos T/imunologia , Animais , Antígenos de Neoplasias/imunologia , Vacinas Anticâncer/uso terapêutico , Células Dendríticas/metabolismo , Endossomos/imunologia , Endossomos/metabolismo , Humanos , Imunidade Inata/imunologia , Complexo Principal de Histocompatibilidade/imunologia , Mimetismo Molecular/imunologia , Subpopulações de Linfócitos T/metabolismo , Receptores Toll-Like/imunologia , Receptores Toll-Like/metabolismoRESUMO
Chemoresistance represents a major problem in the treatment of many malignancies. Overcoming this obstacle will require improved understanding of the mechanisms responsible for this phenomenon. The progenitor cell marker NG2/melanoma proteoglycan (MPG) is aberrantly expressed by various tumors, but its role in cell death signaling and its potential as a therapeutic target are largely unexplored. We have assessed cytotoxic drug-induced cell death in glioblastoma spheroids from 15 patients, as well as in five cancer cell lines that differ with respect to NG2/MPG expression. The tumors were treated with doxorubicin, etoposide, carboplatin, temodal, cisplatin and tumor necrosis factor (TNF)alpha. High NG2/MPG expression correlated with multidrug resistance mediated by increased activation of alpha3beta1 integrin/PI3K signaling and their downstream targets, promoting cell survival. NG2/MPG knockdown with shRNAs incorporated into lentiviral vectors attenuated beta1 integrin signaling revealing potent antitumor effects and further sensitized neoplastic cells to cytotoxic treatment in vitro and in vivo. Thus, as a novel regulator of the antiapoptotic response, NG2/MPG may represent an effective therapeutic target in several cancer subtypes.
Assuntos
Antígenos/fisiologia , Neoplasias Encefálicas/metabolismo , Resistencia a Medicamentos Antineoplásicos , Glioma/metabolismo , Integrinas/fisiologia , Fosfatidilinositol 3-Quinases/metabolismo , Proteoglicanas/fisiologia , Proteínas Proto-Oncogênicas c-akt/metabolismo , Transdução de Sinais , Apoptose/fisiologia , Neoplasias Encefálicas/patologia , Ativação Enzimática , Glioma/patologia , Humanos , Fator de Necrose Tumoral alfa/fisiologiaRESUMO
The discovery that nucleic acids mediated the inhibition of gene expression in a sequence-specific manner has provided the scientific community with a potentially important tool to analyse gene function and validate drug targets. Selective inhibition of gene expression by ribozymes and small interfering RNAs (siRNAs) is being explored for potential therapeutics against viral infections, inflammatory disorders, haematological diseases and cancer. In order to be used as pharmaceutical drugs, chemical modifications are necessary to increase their stability in vivo. However, such modifications should not affect either the ribozyme cleavage activity or the incorporation of the siRNAs into the RNA interference (RNAi) targeting complex and subsequent mRNA cleavage. To attain stability, ribozymes and siRNAs must also overcome several other problems, including accessibility to target messenger RNAs (mRNAs), efficient delivery to target cells and unwanted non-specific effects.
Assuntos
RNA Catalítico/genética , RNA Catalítico/uso terapêutico , RNA Interferente Pequeno/genética , RNA Interferente Pequeno/uso terapêutico , Desenho de Fármacos , Terapia Genética , Humanos , Neoplasias/terapia , Conformação de Ácido Nucleico , RNA Catalítico/química , RNA Interferente Pequeno/química , Ribonucleases/genética , Ribonucleases/metabolismo , Células Estromais/efeitos dos fármacosRESUMO
Human myeloma proteins (HMPs) from 10 patients with multiple myeloma (MM) were used to affinity-select peptides from a random phage-display peptide library. Binding peptides were identified for the 10 analysed antibodies (eight, immunoglobulin G (IgG), and two, immunoglobulin A (IgA)). The specificity of the binding was confirmed by competitive experiments using phages and chemically synthesized peptides. Interestingly, some phage-displayed peptides were immuno-selected with HMPs isolated from different patients. Sequence alignments and homology searches revealed a significant homology with human proteins (e.g. neural cell adhesion proteins) and pathogen-derived proteins (e.g. herpes simplex virus capsid proteins). The selected peptides could be useful as targeting agents for myeloma cells expressing surface immunoglobulins.
Assuntos
Mieloma Múltiplo/genética , Mieloma Múltiplo/imunologia , Proteínas do Mieloma/genética , Proteínas do Mieloma/imunologia , Sequência de Aminoácidos , Anticorpos Antineoplásicos/metabolismo , Especificidade de Anticorpos , Ligação Competitiva , Humanos , Imunoglobulina A/metabolismo , Imunoglobulina G/metabolismo , Técnicas In Vitro , Dados de Sequência Molecular , Proteínas do Mieloma/metabolismo , Biblioteca de Peptídeos , Ligação Proteica , Homologia de Sequência de AminoácidosRESUMO
The identification of immunogenic antigens for serological testing and vaccine development is a major challenge facing cancer immunology research. To study the humoral immune response in patients with breast cancer, a T7 phage display cDNA library from an invasive ductal breast carcinoma was panned on patient serum IgG antibodies. By monitoring the selection with an immunoscreening technique, positive phage-displayed cDNA products reacting with breast cancer patient IgG antibodies were selected. Sequence analysis identified immunogenic antigens such as the cytochrome oxidase I, sp100 and Ran GTPase activating protein. Additionally, immunogenic uncharacterized gene products were also identified. Both the known and unknown immunoselected gene products should offer an additional source for cancer gene discovery for diagnostic testing and vaccine development.
Assuntos
Antígenos de Neoplasias/imunologia , Antígenos Nucleares , Neoplasias da Mama/imunologia , Carcinoma Ductal de Mama/imunologia , Anticorpos Antineoplásicos/imunologia , Autoantígenos/genética , Autoantígenos/imunologia , Autoantígenos/metabolismo , Bacteriófago M13/genética , Western Blotting , Neoplasias da Mama/genética , Neoplasias da Mama/metabolismo , Carcinoma Ductal de Mama/genética , Carcinoma Ductal de Mama/metabolismo , Primers do DNA/química , Complexo IV da Cadeia de Transporte de Elétrons/genética , Complexo IV da Cadeia de Transporte de Elétrons/imunologia , Complexo IV da Cadeia de Transporte de Elétrons/metabolismo , Ensaio de Imunoadsorção Enzimática , Escherichia coli/genética , Feminino , Biblioteca Gênica , Humanos , Immunoblotting , Imunoglobulina G/imunologia , Invasividade Neoplásica , Proteínas Nucleares/genética , Proteínas Nucleares/imunologia , Proteínas Nucleares/metabolismo , Biblioteca de Peptídeos , Reação em Cadeia da Polimerase , Células Tumorais Cultivadas , Proteína ran de Ligação ao GTP/genética , Proteína ran de Ligação ao GTP/imunologia , Proteína ran de Ligação ao GTP/metabolismoRESUMO
Tumor necrosis factor-alpha (TNF-alpha) probably affects the pathogenesis of heart failure. Here we have investigated the therapeutic potential of a nuclease-resistant DNA enzyme that specifically cleaves TNF-alpha mRNA. A phosphorothioate-modified DNA enzyme was designed to retain similar cleavage activity as its unmodified version, and that inhibited the expression of TNF-alpha in vitro. To test its efficacy in vivo, postinfarction congestive heart failure was induced in anesthetized rats by ligation of the left coronary artery. A 4-wk treatment with the DNA enzyme induced a substantial reduction in left ventricular end-diastolic pressure and lung weight concomitant with an increase in arterial blood pressure and myocardial blood flow compared with controls. The concentration of TNF-alpha in coronary sinus blood was markedly lowered on treatment, and myocardial TNF-alpha mRNA was substantially reduced. Recovery studies showed that the DNA enzyme cleavage activity was present within the myocardium throughout the observation period and had no apparent toxic effects. Our findings indicate that DNA enzyme-based therapy may hold promise in the treatment of this debilitating disease.
Assuntos
Enzimas/farmacologia , Insuficiência Cardíaca/tratamento farmacológico , Infarto do Miocárdio/tratamento farmacológico , Fator de Necrose Tumoral alfa/genética , Animais , Enzimas/síntese química , Insuficiência Cardíaca/fisiopatologia , Hemodinâmica , Masculino , Infarto do Miocárdio/fisiopatologia , RNA Mensageiro/metabolismo , Ratos , Ratos Wistar , TransfecçãoRESUMO
BACKGROUND: Activation of the extracellular signal-regulated kinases ERK1 and ERK2 in hepatocytes by prostaglandin (PG)F2alpha was recently found to be inhibited by pertussis toxin (PTX) suggesting a role for Gi proteins. RESULTS: Targeting the Gi2alpha expression by a specific ribozyme inhibited the PGF2alpha -induced ERK1/2 activation in hepatocytes. On the other hand a non-cleaving form of the Gi2alpha ribozyme did not significantly decrease the ERK1/2 activation. In ribozyme-treated cells the Gi2alpha protein level was reduced, while the Gqalpha level was not affected thus confirming the specificity of the ribozyme. CONCLUSION: The present data suggest an important role of Gi2 in PGF2alpha -induced ERK1/2 signaling in hepatocytes.
Assuntos
Subunidades alfa Gi-Go de Proteínas de Ligação ao GTP/fisiologia , Hepatócitos/enzimologia , Proteína Quinase 1 Ativada por Mitógeno/metabolismo , Proteínas Quinases Ativadas por Mitógeno/metabolismo , Proteínas Proto-Oncogênicas/fisiologia , Animais , Células Cultivadas , Dinoprosta/farmacologia , Ativação Enzimática , Inibidores Enzimáticos/farmacologia , Subunidade alfa Gi2 de Proteína de Ligação ao GTP , Subunidades alfa Gi-Go de Proteínas de Ligação ao GTP/genética , Hepatócitos/efeitos dos fármacos , Masculino , Proteína Quinase 3 Ativada por Mitógeno , Toxina Pertussis/farmacologia , Proteínas Proto-Oncogênicas/genética , RNA Catalítico/farmacologia , Ratos , Ratos WistarRESUMO
BACKGROUND: Profiling the immune responses in patients with cancer is expected to facilitate the design of diagnostic tests and therapeutic vaccines. Such studies usually require the parental antigens. We attempted to profile the immune responses in patients with breast cancer using a peptide phage display selection strategy, which identifies antibody specificities whether or not the antigens are known. MATERIALS AND METHODS: A panel of random peptide phage libraries was panned on serum IgG antibodies from breast cancer patients with stage IV, seeking for disease specific IgG epitopes. ELISA, immunoscreening, and Western blotting techniques were the main approaches used. RESULTS: Phage-displayed peptides were specifically enriched for binding to IgG antibodies from patients with breast cancer. Several peptides have been identified, in particular the SQRIPARIHHFPTSI peptide, which was recognized by IgG antibodies from breast cancer patients, but not from normals (p < 0.0004). In patients who responded to the selected peptides, in particular the SQRIPARIHHFPTSI peptide, antibodies against a 66 kDa cellular protein were found. Interestingly, three out of six patients with the strongest immunoreactivity are still alive, with a mean survival time from first recurrence until now of 2553 days. In contrast, all the nonresponders (n = 10) are deceased. The mean survival time of these patients was 784 days, whereas the mean survival time of the three deceased responders was 1050 days (p < 0.02). CONCLUSIONS: The data provide the first example in which panning of peptide phage display libraries on patient IgG antibodies results in the isolation of breast cancer specific IgG epitopes, some of which correlate with patient survival time. Thus, the identified B-cell epitopes should be of great interest in vaccine development.
Assuntos
Neoplasias da Mama/imunologia , Imunoglobulina G/sangue , Imunoglobulina G/imunologia , Sequência de Aminoácidos , Ligação Competitiva , Western Blotting , Membrana Celular/metabolismo , Núcleo Celular/metabolismo , Citosol/metabolismo , Intervalo Livre de Doença , Relação Dose-Resposta a Droga , Ensaio de Imunoadsorção Enzimática , Epitopos/química , Feminino , Humanos , Cinética , Dados de Sequência Molecular , Biblioteca de Peptídeos , Peptídeos/químicaRESUMO
Display on the surface of filamentous phages has been shown to be well suited for the enrichment of serum antibody-binding ligands. Here, we have taken the advantage of this technology to analyze the humoral immune response in patients with cancer. The cDNA repertoires from breast cancer cell lines T47D and MCF-7 were fused to the 3'-end of the filamentous phage M13 gene VI in all three reading frames. When the libraries were biopanned on rabbit polyclonal IgG against the human Bcl-x(L) protein, positive clones were selected, thus confirming the utility of the libraries. Using serum antibodies from patients with breast cancer, we specifically selected IgG-binding phage-encoded cDNA products. Sequence analysis of the selected clones identified important antigens including p53, centromere-F, int-2, pentraxin I, integrin beta5, cathepsin L2 and S3 ribosomal protein. The selected phage-displayed cDNA products were recognized by a significant number of breast cancer sera as compared to sera from normal individuals. Although the human pentraxin I mRNA was reported to be exclusively localized in the nervous system, we found it also expressed by breast cancer cell lines. Four out of 30 patients with breast cancer (13 %) showed reactivity with the recombinant pentraxin expressed in Escherichia coli, while no reactivity was found in normal sera. The obtained results demonstrate that phage display could be a valuable method for the identification of antigens recognized by the humoral immune system in patients with cancer.
Assuntos
Antígenos de Neoplasias/imunologia , Neoplasias da Mama/imunologia , Biblioteca de Peptídeos , Anticorpos Antineoplásicos/imunologia , Bacteriófago M13/genética , Neoplasias da Mama/genética , Neoplasias da Mama/metabolismo , Proteína C-Reativa/biossíntese , Proteína C-Reativa/genética , Proteína C-Reativa/imunologia , Escherichia coli/genética , Feminino , Biblioteca Gênica , Humanos , Immunoblotting , Imunoglobulina G/imunologia , Proteínas do Tecido Nervoso/biossíntese , Proteínas do Tecido Nervoso/genética , Proteínas do Tecido Nervoso/imunologia , RNA Mensageiro/biossíntese , Análise de Sequência de Proteína , Transfecção , Células Tumorais CultivadasRESUMO
The display of human antibody repertoire on the cell surface of the filamentous bacteriophage has offered a novel strategy for selecting antibodies to a diverse range of purified targets. However, the selection of antibodies with biological functions has not yet been fully investigated. To select phage antibodies with therapeutic potential, a synthetic human single chain Fv (scFv) phage antibody library was panned on whole premyelocytic leukemia cell line (HL60). Phages binding to common receptors and undesirable phages were subtracted by incubating the library with human glioma cells. High affinity binding phages to HL60 cells were enriched by fluorescence-activated cell sorting. After the 6th round of selection, 50% of the selected phage antibodies showed significant binding to HL60 cells, whereas none of the analyzed phage antibodies bound to human pre-B cells (Nalm-6). In addition to binding, one scFv antibody inhibited HL60 cell proliferation by 90% compared to irrelevant scFv antibodies. Taken together the data demonstrate that specific scFv antibodies with biological functions can be isolated by using whole cells as affinity matrix.
Assuntos
Fragmentos Fab das Imunoglobulinas/imunologia , Fragmentos Fab das Imunoglobulinas/uso terapêutico , Leucemia Mieloide/tratamento farmacológico , Leucemia Mieloide/imunologia , Biblioteca de Peptídeos , Especificidade de Anticorpos/imunologia , Linfócitos B/imunologia , Western Blotting , Divisão Celular/efeitos dos fármacos , Citometria de Fluxo , Glioma/imunologia , Células HL-60 , Humanos , Fragmentos Fab das Imunoglobulinas/genética , Fragmentos Fab das Imunoglobulinas/farmacologia , Leucemia Mieloide/patologia , Lesões Pré-Cancerosas/tratamento farmacológico , Lesões Pré-Cancerosas/imunologia , Lesões Pré-Cancerosas/patologia , Células Tumorais CultivadasRESUMO
Recent molecular and cellular studies have highlighted the important role of some gene products in the cause and/or perpetuation of human pathological conditions including cancer and autoimmune diseases. The identification of such gene products has led to the development of new candidate therapies. The discovery of catalytic nucleic acid enzymes has provided researchers with a potentially important tool to block the expression of abnormal genes, provided that their sequences are known. The cleavage specificity of these compounds is determined by their hybridizing antisense arms, which anneal with the target mRNA in a complementary fashion. Nucleic acid enzymes can be delivered to cells either endogenously as gene encoding RNA enzymes (ribozymes) or exogenously as in vitro made agents. Given the progress reported during the last years, a wide range of molecular designs and chemical modifications can be introduced into these compounds, in particular the hammerhead type ribozyme. Here, we review the design, stability and the therapeutic application of these agents with the goals of illustrating relevant gene targets and signal pathways for molecular medicine. Relevant in vivo problems of the technology, mRNA repair by group I intron ribozymes and gene regulation by endogenous RNA will also be discussed.
Assuntos
RNA Catalítico/uso terapêutico , Animais , Apoptose , Sequência de Bases , DNA Catalítico/química , DNA Catalítico/genética , DNA Catalítico/uso terapêutico , DNA de Cadeia Simples/química , DNA de Cadeia Simples/genética , DNA de Cadeia Simples/uso terapêutico , Sistemas de Liberação de Medicamentos , Desenho de Fármacos , Humanos , Modelos Biológicos , Dados de Sequência Molecular , Neoplasias/genética , Neoplasias/terapia , Conformação de Ácido Nucleico , Splicing de RNA , RNA Catalítico/química , RNA Catalítico/genética , Transdução de SinaisRESUMO
Recent progress in understanding how gene products interact in the control of cell proliferation has engendered high hopes for the rational design of specific therapeutic strategies. The demonstration that certain RNA and DNA nucleic acids can enzymatically cleave mRNAs has offered the possibility of inactivating abnormal gene expression. In principle, this technology is applicable to any disease where a specific gene product can be linked to the initiation and/or perpetuation of the disease. Here, a brief description of the technology that can be useful for the design of therapeutic DNA and RNA agents capable of inducing apoptosis in cancer cells is presented. Furthermore, such agents can be a valuable tool for probing gene function.
Assuntos
DNA Catalítico/uso terapêutico , Neovascularização Patológica/tratamento farmacológico , RNA Catalítico/uso terapêutico , Animais , DNA Catalítico/metabolismo , Desoxirribonucleases/metabolismo , Desenho de Fármacos , Humanos , Conformação de Ácido Nucleico , RNA Catalítico/metabolismo , RNA Mensageiro/metabolismo , Ribonucleases/metabolismo , Transdução de Sinais/efeitos dos fármacosRESUMO
The Bcl-2 family of proteins has been shown to play a central role in the regulation of apoptosis. We have examined the expression of several Bcl-2 homologs upon stimulation of CD34(+) human hematopoietic progenitor cells. CD34(+) cells were induced to differentiate into predominantly erythroid cells in the presence of erythropoietin (Epo) and stem cell factor (SCF), while the addition of G-CSF and SCF led to differentiation predominantly into granulocytic cells, as demonstrated by immunophenotyping and morphological examination of cultured cells. In Epo- and SCF-stimulated cells, we found a marked increase in the level of Bcl-x(L) protein expression and downregulation of Bax expression, apparent from day 4 and more pronounced on days 8 and 21. In contrast, Bcl-x(L) protein expression was downregulated in G-CSF- and SCF-stimulated cells compared with cells cultured in medium alone, whereas there was no sign of change in the level of Bax. Mcl-1 expression showed a biphasic expression pattern in both early erythropoiesis and early granulopoiesis, but with an inverse regulation. Thus, Mcl-1 levels initially decreased in granulocytic progenitor cells and increased in erythroid progenitor cells. Finally, Bcl-2 expression was significantly downregulated in both Epo and SCF and G-CSF- and SCF-stimulated cells. The role of the distinct upregulation of Bcl-x(L) in early erythroid differentiation was further examined by use of specific ribozymes against Bcl-x(L). Addition of Bcl-x(L) ribozymes promoted a clear increase in cell death of Epo- and SCF-stimulated cells, while erythroid differentiation was not affected. In conclusion, we found a distinct regulation of several Bcl-2 family members in CD34(+) cells dependent on the cytokine stimulation given. The use of Bcl-x(L)-specific ribozymes suggested that Bcl-x(L) is important for survival but not for differentiation of erythroid progenitor cells.
Assuntos
Antígenos CD34 , Células Precursoras Eritroides/metabolismo , Granulócitos/metabolismo , Células-Tronco Hematopoéticas/metabolismo , Proteínas de Neoplasias/biossíntese , Proteínas Proto-Oncogênicas c-bcl-2/biossíntese , Proteínas Proto-Oncogênicas/biossíntese , Adulto , Biomarcadores , Diferenciação Celular , Linhagem da Célula , Sobrevivência Celular , Células Cultivadas , Células Precursoras Eritroides/citologia , Células Precursoras Eritroides/efeitos dos fármacos , Eritropoetina/farmacologia , Fator Estimulador de Colônias de Granulócitos/farmacologia , Granulócitos/citologia , Granulócitos/efeitos dos fármacos , Células-Tronco Hematopoéticas/citologia , Células-Tronco Hematopoéticas/efeitos dos fármacos , Humanos , Proteína de Sequência 1 de Leucemia de Células Mieloides , RNA Catalítico , Fator de Células-Tronco/farmacologia , Proteína X Associada a bcl-2 , Proteína bcl-XRESUMO
Peptide and cDNA phage display libraries can be used to determine the specificities of antibodies present in the whole sera of patients where information about the parental antigens is unknown. In this respect, patient serum antibody binding ligands have been identified. Such ligands would facilitate the design of diagnostic assays and therapeutic vaccines. In the case of cancer, this novel technology is expected to improve our understanding of the immune responses against tumour cells and to discriminate between autoantigen and true tumour specific antigens. Here, we review work on how peptide and cDNA phage display libraries can be used to address the specificity of the immune responses in patients with autoimmune diseases and cancer.
Assuntos
Anticorpos Antineoplásicos/análise , Anticorpos/análise , Doenças Autoimunes/imunologia , Biblioteca Gênica , Neoplasias/imunologia , Biblioteca de Peptídeos , Animais , Anticorpos/imunologia , Anticorpos Antineoplásicos/imunologia , Especificidade de Anticorpos , Autoanticorpos/análise , Autoanticorpos/imunologia , Doenças Autoimunes/diagnóstico , Biomarcadores , Humanos , Imunoensaio/métodos , Modelos Biológicos , Neoplasias/diagnósticoRESUMO
For the therapeutic application of catalytic nucleic acids it is desirable to have small, stable and inexpensive compounds that are active at physiological Mg(2+) concentrations. We have explored the possibility of using the versatile 10-23 DNA catalytic core to suppress the expression of the protein kinase Calpha (PKCalpha) isoform in malignant cells. By introducing either a 3'-3'-inverted thymidine nucleotide or site-specific phosphorothioate modification into a PKCalpha DNA enzyme, we have designed stable catalysts that retained a significant in vitro cleavage activity. In particular, a DNA enzyme containing phosphorothioate analogues in the antisense arms and in the pyrimidine residues of the catalytic core was found to be remarkably stable in 50 % human serum (t(1/2)>90 hours) and inhibited in vitro cell growth by up to 90 % at nanomolar concentrations. The inhibition of PKCalpha gene expression is sequence-specific, as a DNA enzyme with reversed antisense arms was found to be ineffective. Epifluorescence microscopic analysis of cells transfected with a 5' fluorescein isothiocyanate-conjugated DNA enzyme showed that the DNA enzyme molecules are mainly localised in the nuclei. Most of the DNA enzyme-treated cells were killed by apoptosis. The ability of the described PKCalpha DNA enzymes to trigger apoptosis (apoptozymes) in malignant cells illustrates their therapeutic potential. Furthermore, such agents can be a valuable tool for probing gene function.
Assuntos
DNA de Cadeia Simples/metabolismo , DNA de Cadeia Simples/uso terapêutico , Desoxirribonucleases/metabolismo , Isoenzimas/genética , Proteína Quinase C/genética , Apoptose/efeitos dos fármacos , Sequência de Bases , Transporte Biológico , Catálise , Divisão Celular/efeitos dos fármacos , Núcleo Celular/enzimologia , Tamanho Celular/efeitos dos fármacos , DNA Antissenso/genética , DNA Antissenso/metabolismo , DNA Antissenso/farmacologia , DNA Antissenso/uso terapêutico , DNA Catalítico , DNA de Cadeia Simples/genética , DNA de Cadeia Simples/farmacologia , Desoxirribonucleases/sangue , Desenho de Fármacos , Estabilidade Enzimática , Regulação Enzimológica da Expressão Gênica/efeitos dos fármacos , Terapia Genética , Meia-Vida , Humanos , Isoenzimas/antagonistas & inibidores , Lipossomos/administração & dosagem , Mitocôndrias/enzimologia , Peso Molecular , Mutação/genética , Proteína Quinase C/antagonistas & inibidores , Proteína Quinase C-alfa , Especificidade por Substrato , Células Tumorais CultivadasRESUMO
Protein kinase C (PKC) is a family of serine/threonine protein kinases involved in many cellular responses. Although the analysis of PKC activity in many systems has provided crucial insights to its biologic function, the precise role of different isoforms on the differentiation of normal hematopoietic progenitor cells into the various lineages remains to be investigated. The authors have assessed the state of activation and protein expression of PKC isoforms after cytokine stimulation of CD34(+) progenitor cells from human bone marrow. Freshly isolated CD34(+) cells were found to express PKC-alpha, PKC-beta2, and PKC-epsilon, whereas PKC-delta, PKC-gamma, and PKC-zeta were not detected. Treatment with erythropoietin (EPO) or with EPO and stem cell factor (SCF) induced a predominantly erythroid differentiation of CD34(+) cells that was accompanied by the up-regulation of PKC-alpha and PKC-beta2 protein levels (11.8- and 2.5-fold, respectively) compared with cells cultured in medium. Stimulation with EPO also resulted in the nuclear translocation of PKC-alpha and PKC-beta2 isoforms. Notably, none of the PKC isoforms tested were detectable in CD34(+) cells induced to myeloid differentiation by G-CSF and SCF stimulation. The PKC inhibitors staurosporine and calphostin C prevented EPO-induced erythroid differentiation. Down-regulation of the PKC-alpha, PKC-beta2, and PKC-epsilon expression by TPA pretreatment, or the down-regulation of PKC-alpha with a specific ribozyme, also inhibited the EPO-induced erythroid differentiation of CD34(+) cells. No effect was seen with PKC-beta2-specific ribozymes. Taken together, these findings point to a novel role for the PKC-alpha isoform in mediating EPO-induced erythroid differentiation of the CD34(+) progenitor cells from human bone marrow. (Blood. 2000;95:510-518)
Assuntos
Diferenciação Celular/fisiologia , Eritropoetina/farmacologia , Células-Tronco Hematopoéticas/citologia , Células-Tronco Hematopoéticas/fisiologia , Isoenzimas/genética , Proteína Quinase C/genética , Adulto , Antígenos CD/análise , Antígenos CD34 , Células da Medula Óssea/citologia , Diferenciação Celular/efeitos dos fármacos , Núcleo Celular/enzimologia , Células Cultivadas , Inibidores Enzimáticos/farmacologia , Regulação Enzimológica da Expressão Gênica/efeitos dos fármacos , Fator Estimulador de Colônias de Granulócitos/farmacologia , Células-Tronco Hematopoéticas/efeitos dos fármacos , Humanos , Isoenzimas/metabolismo , Naftalenos/farmacologia , Proteína Quinase C/metabolismo , Proteína Quinase C beta , Proteína Quinase C-alfa , Proteínas Recombinantes/farmacologia , Estaurosporina/farmacologia , Fator de Células-Tronco/farmacologia , Acetato de Tetradecanoilforbol/farmacologiaRESUMO
Protein kinase C is a family of serine/threonine protein kinases involved in many cellular responses, including cell survival and apoptosis. We have recently found that specific inhibition of the PKCalpha isoform by nucleic acid enzymes induced apoptosis in sensitive cells. Here we show that in PKCalpha DNA enzyme-treated glioma cells the activation of MAP kinases ERK1/2 is inhibited, whereas their total level was not significantly affected by the treatment. Similar results were obtained when the overall activity of the PKC was inhibited by calphostin, a specific inhibitor for PKC. These results would indicate that the ERK1/2 signaling pathway plays an important role in glioma cell survival and that the PKCalpha isoform is the main modulator of this pathway. Furthermore, we show that the ERK1/2 signaling pathway is required for the constitutive expression of the basic fibroblast growth factor, a potent mitogen for glioma cell growth.
Assuntos
Sobrevivência Celular/fisiologia , Glioma/enzimologia , Isoenzimas/fisiologia , Sistema de Sinalização das MAP Quinases/fisiologia , Proteínas Quinases Ativadas por Mitógeno/metabolismo , Proteína Quinase C/fisiologia , Células Tumorais Cultivadas/efeitos dos fármacos , Western Blotting , Ativação Enzimática/fisiologia , Inibidores Enzimáticos/farmacologia , Matriz Extracelular/enzimologia , Fator 2 de Crescimento de Fibroblastos/metabolismo , Flavonoides/farmacologia , Expressão Gênica , Glioma/patologia , Humanos , Isoenzimas/antagonistas & inibidores , Proteínas Quinases Ativadas por Mitógeno/antagonistas & inibidores , Naftalenos/farmacologia , Proteína Quinase C/antagonistas & inibidores , Proteína Quinase C-alfaRESUMO
Although protein kinase C has been shown to be involved in a wide range of biological functions, the precise role of each isoform in a specific cell function remains to be clarified. Here we demonstrate that a ribozyme specific for the human protein kinase C alpha (PKC alpha), a classical PKC isoform, induces cell death in glioma cell lines. This cell death was identified as apoptosis by morphologic alterations and endonucleosomal DNA fragmentation. The inhibition of PKC alpha gene expression by the ribozyme resulted in a significant reduction in Bcl-xL gene expression, a protein that inhibits apoptosis and is overexpressed in glioma cells. Taken together, our data suggest that the PKC alpha ribozymes are a potent inducer of apoptosis in glioma cells, which may act through suppressing Bcl-xL gene expression and/or activity. PKC alpha ribozymes may prove useful in the management of malignant gliomas.